1830 (1830) Fair Value & Analysis

Healthcare · Market cap HK$1.5B

1 1830 1830 · HK

PriceHK$1.19

Fair ValueHK$3.06

Upside+157.1%

Quality67/100

Watch 1830 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$2.24 – HK$3.88

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price +3.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.06 – HK$1.67 · fair‑value band HK$2.24 – HK$3.88 · the HK$1.19 price screens below the HK$3.06 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1830 (1830) currently trades at HK$1.19, while our model-based Fair Value estimate is HK$3.06 — implying the stock looks roughly 157.1% undervalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1830 generated revenue of HK$993M at a net margin of 16.2%. Revenue declined 21.7% year over year. It earns a return on equity of 38.3%. The balance sheet holds a net cash position of HK$12.1M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$993M

Revenue growth (YoY) -21.7%

Net margin 16.2%

Return on equity 38.3%

Free cash flow HK$298M FY2025

P/E ratio 8.5

More key figures

Operating margin 22.5%

EPS (TTM) HK$0.1300

Dividend yield 13.5%

EPS growth (YoY) -33.0%

Net cash HK$12.1M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

1830 reported revenue of HK$962M in FY2026 versus HK$1.3B in FY2022, a compound −8.1%/yr. Reported net income was HK$179M in FY2026, compounding −12.5%/yr from FY2022.

Revenue −8.1%/yr

FY22 HK$1.3B

FY23 HK$1.4B

FY24 HK$1.4B

FY25 HK$1.1B

FY26 HK$962M

Net income −12.5%/yr

FY22 HK$305M

FY23 HK$316M

FY24 HK$316M

FY25 HK$207M

FY26 HK$179M

Is 1830 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.71 MYR	4.87 MYR	-44%
IHHHF IHHHF	$1.71	$1.17	-32%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1830 (1830) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$3.06 versus a price of HK$1.19 — about +157% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1830?

Our model-based fair value for 1830 is HK$3.06 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.19.

What is the quality score of 1830?

1830 has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1830 (1830)?

1830 reported trailing-twelve-month revenue of about HK$993M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1830?

The net profit margin of 1830 is about 16.2%, meaning it keeps roughly 16.2% of revenue as net income. Based on the latest reported figures.

Does 1830 pay a dividend?

1830 currently shows a dividend yield of about 13.52% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.